A human neutralizing antibody against a conformational epitope shared by oligomeric SARS S1 protein

Antiviral Therapy

Volumn 11, Issue 1, 2006, Pages 117-123

  Duan, Jinzhu ^a   Ji, Xin ^a   Feng, Jing ^a   Han, Wei ^a   Zhang, Panhe ^b   Cao, Wuchun ^b   Guo, Xueming ^a   Qi, Cai ^a   Yang, Dongling ^a   Jin, Gang ^a   Gao, Guangxia ^a   Yan, Xiyun ^a  

^a INSTITUTE OF BIOPHYSICS   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; NEUTRALIZING ANTIBODY; OLIGOMER; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; VIRUS PROTEIN;

ANIMAL CELL; ANTIGEN BINDING; ARTICLE; B LYMPHOCYTE; COMPETITIVE INHIBITION; DISSOCIATION CONSTANT; ENZYME LINKED IMMUNOSORBENT ASSAY; MONKEY; NONHUMAN; PHAGE DISPLAY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SARS CORONAVIRUS; VERO CELL; VIRION; VIRUS NEUTRALIZATION; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; DIMERIZATION; EPITOPES; HUMANS; IMMUNOGLOBULIN FRAGMENTS; MEMBRANE GLYCOPROTEINS; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PEPTIDE LIBRARY; PROTEIN CONFORMATION; SARS VIRUS; VERO CELLS; VIRAL ENVELOPE PROTEINS;

EID: 33644551578     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Peiris JS, Lai ST, Poon LL, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003; 361:1319-1325.
2. Drosten C, Gunther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003; 348:1967-1976.
3. Ksiazek TG, Erdman D, Goldsmith CS, et al. SARS Working Group. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003; 348:1953-1966.
4. Holmes KV. SARS coronavirus: a new challenge for prevention and therapy. J Clin Invest 2003; 111:1605-1609.
5. Pearson H, Clarke T, Abbott A, Knight J, Cyranoski D. SARS: what have we learned? Nature 2003; 424:121-126
6. Cheng Y, Wong R, Soo YOY, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005; 24:44-46
7. Soo YO, Cheng Y, Wong R, et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect 2004; 10:676-678.
8. Li G, Chen X, Xu A. Profile of specific antibodies to the SARS-associated coronavirus. N Eng J Med 2003; 349:508-509.
9. Xiao X, Feng Y, Chakraborti S, Dimitrov DS. Oligomerization of the SARS-CoV S glycoprotein: dimerization of the N-terminus and trimerization of the ectodomain. Biochem Biophys Res Commun 2004; 322:93-99.
10. Song HC, Seo MY, Stadler K, et al. Synthesis and characterization of a native, oligomeric form of recombinant severe acute respiratory syndrome coronavirus spike glycoprotein. J Virol 2004; 78:10328-10335.
11. Lin Y, Yan X, Cao W, et al. Probing the structure of the SARS coronavirus using scanning electron microscopy. Antivir Ther 2004; 9:287-289.
12. Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003; 426:450-454.
13. Wong SK, Li W, Moore MJ, Choe H, Farzan M. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J Biol Chem 2004; 279:3197-3201.
14. Ho T, Wu S, Cheng S, Wei Y, Huang S, Hsiang C. Antigenicity and receptor-binding ability of recombinant SARS coronavirus spike protein. Biochem Biophys Res Commun 2004; 313:938-947.
15. He Y, Zhou Y, Wu H, et al. Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines. J Immunol 2004; 173:4050-4057.
16. Sui J, Li W, Murakami A, et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAB to S1 protein that blocks receptor association. Proc Natl Acad Sci USA 2004; 101:2536-2641.
17. Van den Brink EN, Ter Meulen J, Cox F, et al. Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus. J Virol 2005; 79:1635-1644.
18. Traggian E, Becker S, Subbarao K, et al. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med 2004; 10:871-875.
19. Yao YX, Ren J, Heinen P, Zambon M, Jones IM. Cleavage and serum reactivity of the severe acute respiratory syndrome coronavirus spike protein. J Infect Dis 2004; 190:91-98.
20. He Y, Zhu Q, Liu S, et al. Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines. Virology 2005; 334:74-82.
21. Sblattero D, Bradbury A. Exploiting recombination in single bacteria to make large phage antibody libraries. Nat Biotechnol 2000; 18:75-80.
22. O'Brien PM, Aitken R. Methods in molecular biology: Antibody phage display methods and protocols. New Jersey: Humana Press; 2002.
23. Borrebaeck CAK, editor. Antibody engineering. 2nd ed. New York: Oxford University Press; 1995.
24. Zhang Z-Q, Lin Y, Yan X-Y. Expression and refolding of an anti-tumor antibody AA98 fragment VH/K. Progress in Biochemistry and Biophysics 2002; 29:645-650.
25. Elwing H. Protein absorption and ellipsometry in biomaterial research. Biomaterials 1998; 19:397-406.
26. Wang ZH, Jin G. A label-free multisensing immunosensor based on imaging ellipsometry. Anal Chem 2003; 75:6119-6123.
27. Malmborg AC, Michaelsson A, Ohlin M, Jansson B, Borrebaeck AK. Real time analysis of antibody-antigen reaction kinetics, Scand J Immunology 1992; 35:643-650.
28. Yang ZY, Huang Y, Ganesh L, et al. pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J Virol 2004; 78:5642-5650.
29. Zhiwei D, Yan W. Antibody Engineering. 2nd ed. Beijing: Peking University Medical Press; 2002.
30. Sblattero D, Bradbury A. A definitive set of oligonucleotide primers for amplifying human V regions. Immunotechnology 1998; 3:271-278.
31. Knappik A, Ge L, Honegger A, et al. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J Mol Biol 2000; 296:57-86.
32. Han DP, Kim HG, Kim YB, Poon LL, Cho MW. Development of a safe neutralization assay for SARS-CoV and characterization of S-glycoprotein. Virology 2004; 326:140-149.
33. Giroglou T, Cinatl J Jr, Rabenau H, et al. Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein. J Virol 2004; 78:9007-9015.
34. Simmons G, Reeves JD, Rennekamp AJ, Amberg SM, Piefer AJ, Bates P. Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc Natl Acad Sci USA 2004; 101:4240-4245.
35. Bernini A, Spiga O, Ciutti A, et al. Prediction of quaternary assembly of SARS coronavirus peplomer. Biochem Biophys Res Commun 2004; 325:1210-1214.
36. Hadlock KG, Rowe J, Foung SK. The humoral immune response to human T-cell lymphotropic virus type 1 envelope glycoprotein gp46 is directed primarily against conformational epitopes. J Virol 1999; 73:1205-1212.
37. Sattentau QJ, Moore JP. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J Exp Med 1995; 182:185-196.